1. Davies, D.S., Thorgeirsson, S.S.: Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta pharmacol. toxicol. (Suppl.) (Kbh.)29, 181?190 (1971)
2. Hvidberg, E.F., Buch Andreasen, P., Ranek, L.: Plasma half-life of phenylbutazone in patients with impaired liver function. Clin. Pharmacol. Ther.15, 171?177 (1974)
3. Kellermann, G., Luyten-Kellermann, M., Horning, M.G., Stafford, M.: Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates of antipyrine and phenylbutazone. Drug Metab. Dispos.3, 47?50 (1975)
4. Bakke, O.M., Draffan, G.H., Davies, D.S.: The metabolism of phenylbutazone in the rat. Xenobiotica4, 237?254 (1974)
5. Burns, J.J., Rose, R.K., Goodwin, S., Reichenthal, J., Horning, E.C., Brodie, B.B.: The metabolic fate of phenylbutazone (Butazolidin) in man. J. Pharmacol. exp. Ther.113, 481?489 (1955)